Special Issue "Recent Developments and Future Perspectives in Dissolution Testing"
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: closed (31 March 2011)
Dr. Jaakko Aaltonen
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211 Kuopio, Finland
Phone: +358 40 3553872
Interests: dissolution testing; dissolution method development; in vitro-in vivo correlation (IVIVC); formulation development
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- dissolution testing
- dissolution method development
- in vitro-in vivo correlation (IVIVC)
- formulation development
Pharmaceutics 2010, 2(4), 351-363; doi:10.3390/pharmaceutics2040351
Received: 12 October 2010; in revised form: 26 October 2010 / Accepted: 28 October 2010 / Published: 1 November 2010| Download PDF Full-text (184 KB)
Pharmaceutics 2010, 2(4), 419-431; doi:10.3390/pharmaceutics2040419
Received: 2 December 2010; in revised form: 13 December 2010 / Accepted: 16 December 2010 / Published: 17 December 2010| Download PDF Full-text (523 KB)
Article: Development of a New Type of Prolonged Release Hydrocodone Formulation Based on Egalet® ADPREM Technology Using In Vivo–In Vitro Correlation
Pharmaceutics 2011, 3(1), 73-87; doi:10.3390/pharmaceutics3010073
Received: 6 February 2011; in revised form: 28 February 2011 / Accepted: 4 March 2011 / Published: 9 March 2011| Download PDF Full-text (444 KB) | Download XML Full-text
Pharmaceutics 2011, 3(2), 315-325; doi:10.3390/pharmaceutics3020315
Received: 13 April 2011; Accepted: 20 June 2011 / Published: 21 June 2011| Download PDF Full-text (272 KB) | Download XML Full-text
Last update: 7 July 2010